Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • secondary banner - 5
  • About Our Center

    Our Mission

    Matthew Meyerson, MD, PhD, and William Hahn, MD, Phd  

    The mission of the Center for Cancer Genome Discovery (CCGD) is to advance precision cancer medicine by developing new technologies for the analysis of cancer genomes and to provide basic, translational, and clinical investigators with access to these technologies.

    The three main components of our mission are:

    • Technology development: To develop new technologies for the analysis of cancer genomes
    • Collaborations: To provide access to these genomic technologies to basic, translational, and clinical investigators at Dana-Farber and beyond
    • Translation: To translate technologies to the clinical setting

    More specifically, we focus on the discovery of genomic alterations in human cancer and evaluate the clinical significance of these alterations for cancer diagnosis and therapy. Our next-generation sequencing platforms allow us to detect the full range of genomic alterations, including:

    • Single nucleotide variants
    • Insertions and deletions
    • Chromosomal rearrangements: translocations, inversions, duplications
    • Copy number changes
    • Expression changes
    • Allele-specific expression
    • Detection and quantification of gene fusion

    An integral aspect of the Center's mission is working toward more effective clinical trial designs, in which patients with similar genetically defined cancers will receive drugs designed to target specific genetic aberrations. In addition to the main areas indicated above, CCGD is available to assist collaborators with funding (e.g., grant submissions), experimental design, and coordination of each project through the appropriate channels.

    Our Structure

    Bioinformatics diagram

    CCGD is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital.

    Profile's mission is to implement these technologies in a CLIA-certified clinical environment with two major aims: potentially identify genetic variants that can dictate targeted therapies that are most likely to be effective in individual patients; and populate a comprehensive research database linking patient clinical data with genetic findings across a wide array of tumor types.

    The Bioinformatics group bridges both efforts by developing sophisticated analytical tools that mine the sequence data, translating results into research and clinical information.

    Learn more about this initiative